In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

被引：91

作者：

Boucher, HW

Wennersten, CB

Eliopoulos, GM

机构：

[1] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA

[2] Harvard Univ, Sch Med, Boston, MA 02115 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 08期

关键词：

D O I：

10.1128/AAC.44.8.2225-2229.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activities of GAR-936, the 9-t-butylglycylamido derivative of minocycline, were compared with those of doxycycline, minocycline, acid tetracycline against 527 gram-positive clinical isolates. GAR-936 inhibited all strains, including those resistant to other tetracyclines, at concentrations of less than or equal to 2 mu g/ml, except two strains of JE; diphtheroids for which the MIC was 4 mu g/ml.

引用

收藏

页码：2225 / 2229

页数：5

相关论文

共 16 条

[1] INVITRO ACTIVITY OF RP59500, AN INJECTABLE STREPTOGRAMIN ANTIBIOTIC, AGAINST VANCOMYCIN-RESISTANT GRAM-POSITIVE ORGANISMS [J].

COLLINS, LA ;

MALANOSKI, GJ ;

ELIOPOULOS, GM ;

WENNERSTEIN, CB ;

FERRARO, MJ ;

MOELLERING, RC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :598-601

[2] Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality [J].

Edmond, MB ;

Ober, JF ;

Dawson, JD ;

Weinbaum, DL ;

Wenzel, RP .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (06) :1234-1239

[3] INVITRO ACTIVITY OF SCH-29482 IN COMPARISON WITH OTHER ORAL ANTIBIOTICS [J].

ELIOPOULOS, GM ;

GARDELLA, A ;

MOELLERING, RC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1982, 9 :143-152

[4] IN-VITRO ACTIVITIES OF 2 GLYCYLCYCLINES AGAINST GRAM-POSITIVE BACTERIA [J].

ELIOPOULOS, GM ;

WENNERSTEN, CB ;

COLE, G ;

MOELLERING, RC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (03) :534-541

[5] Vancomycin-resistant enterococci - Mechanism and clinical relevance [J].

Eliopoulos, GM .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1997, 11 (04) :851-&

[6] Determinants of vancomycin use in adult intensive care units in 41 United States hospitals [J].

Fridkin, SK ;

Edwards, JR ;

Pichette, SC ;

Pryor, ER ;

McGowan, JE ;

Tenover, FC ;

Culver, DH ;

Gaynes, RP .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1119-1125

[7] Drug therapy - Antimicrobial-drug resistance [J].

Gold, HS ;

Moellering, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (19) :1445-1453

[8] Risk factors for hospital-acquired Staphylococcus aureus bacteremia [J].

Jensen, AG ;

Wachmann, CH ;

Poulsen, KB ;

Espersen, F ;

Scheibel, J ;

Skinhoj, P ;

Frimodt-Moller, N .

ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (13) :1437-1444

[9] Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary [J].

Landman, D ;

Chockalingam, M ;

Quale, JM .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1062-1066

[10]

Moellering RC, 1998, CLIN INFECT DIS, V26, P1177, DOI 10.1086/520288